MedicalResearch.com Interview with:
Igho Onakpoya MD MSc
University of Oxford
Centre for Evidence-Based Medicine
Nuffield Department of Primary Care Health Sciences
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Several medicines used to treat obesity have been withdrawn from the market over the last few years. However, the reasons for, and time trends about their withdrawals have not been systematically researched.
We identified 25 anti-obesity medicines withdrawn from the market over the last 50 years. 23 of these analogues of amphetamine or fenfluramine, i.e., neurotransmitters.
The reasons for withdrawal in the overwhelming majority of instances were cardiovascular or psychiatric adverse reactions, and drug abuse and dependence.
MedicalResearch.com: What should readers take away from your report?
Response: The use of medicines with centrally-acting mechanisms of action to treat obesity put patients at increased risks of serious unwanted effects.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: Greater transparency in the reporting of harms in clinical trials of medicines intended to be used for obesity treatment should be encouraged.
MedicalResearch.com: Is there anything else you would like to add?
Response: The use of centrally-acting medicines to treat obesity is associated with unfavourable benefit-to-harm balance.
We should therefore re-think the use of this class of agents for obesity management.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review
Igho J. Onakpoya, Carl J. Heneghan and Jeffrey K. Aronson
Published: 29 November 2016
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
More Medical Research Interviews on MedicalResearch.com